Kensey Nash Corporation (Kensey), a medical devices company, has appointed Michael Celano as its chief financial officer (CFO), effective March 10, 2009. Celano most recently served as the managing director of Aon Corporation's national life sciences practice. Celano was also the chief financial officer for BioRexis Pharmaceutical Corp. Prior to that, Celano spent 24 years as a partner with KPMG and Arthur Andersen.
At Aon Corporation,. Celano led business development activities in key U.S. markets focused on product/clinical trial and D&O enterprise risk.. Celano is also on the board of a publicly held medical diagnostics company. Celano served over 40 life sciences clients and was the lead audit partner for sixteen different public life sciences companies. Further, he was the lead partner on twenty-two initial public offerings, and he has worked on over 100 public offerings and over sixty corporate partner and merger/acquisition transactions. After his public accounting experience, Celano became the chief financial officer for BioRexis Pharmaceutical Corporation, a privately held venture-funded company that was acquired by Pfizer in February 2007.
“We are looking forward to Mike joining our management team where his extensive and broad experience as a partner with KPMG and Arthur Andersen in the life sciences practice along with his success as a CFO in the private sector will be a valuable resource,” stated Joe Kaufmann, president and chief executive officer. “On behalf of the Board, I would like to welcome Mike to the Kensey Nash management team.”